Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRAL-SMALL: durvalumab with concurrent vs sequential thoracic radiotherapy in ED-SCLC
jRCTs071200101Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab in small cell lung cancer (SCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Incidence of ≥ Grade 2 pneumonitis within 6 months from the start of radiation therapy. Started Mar 2021; status: recruiting.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCTs071200101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071200101.